{"id":943476,"date":"2026-03-11T08:08:08","date_gmt":"2026-03-11T12:08:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/"},"modified":"2026-03-11T08:08:08","modified_gmt":"2026-03-11T12:08:08","slug":"arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/","title":{"rendered":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders"},"content":{"rendered":"
\n

\n \u2013 Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease \u2013<\/em>\n <\/p>\n

NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease (PD) will be presented at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas\u2019 investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in PD and progressive supranuclear palsy (PSP).<\/p>\n

\n Presentation details are as follows:<\/strong>\n <\/p>\n

\n Presentation Title: <\/strong>Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants with Parkinson\u2019s Disease<\/p>\n

\n Session Title: <\/strong>Modulating Neuroinflammation, \u0391-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data<\/p>\n

\n Session Type: <\/strong>Symposium<\/p>\n

\n Session Location: <\/strong>Hall 180-181\u00a0<\/p>\n

\n Date:<\/strong>\u00a0March 18, 2026<\/p>\n

\n Lecture Time:<\/strong>\u00a03:30-3:45 PM CET<\/p>\n

The full abstract can be accessed via the AD\/PD\u2122 2026 interactive program<\/a>.<\/p>\n

\n About ARV-102<\/strong>\n <\/p>\n

ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and overexpression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including Parkinson\u2019s disease and progressive supranuclear palsy (PSP). ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson\u2019s disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the first half of 2026.<\/p>\n

About Arvinas<\/strong><\/p>\n

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+\/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit\u00a0www.arvinas.com<\/strong><\/a>\u00a0and connect on\u00a0LinkedIn<\/strong><\/a>\u00a0and\u00a0X<\/strong><\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2, and potential future benefit to patients; and Arvinas\u2019 plans with respect to ARV-102, including, pending regulatory feedback, the initiation of a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy, and the timing thereof. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas\u2019 strategy, development plans, future operations, prospects, plans and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words \u201cability,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cwhether,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201creliance,\u201d \u201cshould,\u201d \u201clook forward,\u201d \u201cseek,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.<\/p>\n

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas\u2019 ability to protect its intellectual property portfolio; Arvinas\u2019 reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas\u2019 cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release.<\/p>\n

\n Contacts<\/strong>
\n
\n Investors:<\/strong>
\n
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com<\/strong><\/a><\/p>\n

\n Media:<\/strong>
\n
Kirsten Owens
+1 (203) 584-0307
kirsten.owens@arvinas.com<\/strong><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease \u2013 NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease (PD) will be presented at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas\u2019 investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional … <\/p>\n

Continue reading “Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease \u2013 NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease (PD) will be presented at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas\u2019 investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional … Continue reading "Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T12:08:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders\",\"datePublished\":\"2026-03-11T12:08:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/\"},\"wordCount\":876,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/\",\"name\":\"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=\",\"datePublished\":\"2026-03-11T12:08:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk","og_description":"\u2013 Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease \u2013 NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson\u2019s disease (PD) will be presented at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD\u2122 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas\u2019 investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional … Continue reading \"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-11T12:08:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders","datePublished":"2026-03-11T12:08:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/"},"wordCount":876,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/","name":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=","datePublished":"2026-03-11T12:08:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTUzNyM3NDc4NTI2IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurologi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}